International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationRadiotherapy to Improve Local Control Regardless of Surgical Margin and Malignancy Grade in Extremity and Trunk Wall Soft Tissue Sarcoma: A Scandinavian Sarcoma Group Study
Introduction
A high malignancy grade and the quality of the surgical margin are the two most important risk factors for local recurrence (LR) of soft tissue sarcomas (STSs) 1, 2, 3, 4, 5, 6, 7. STSs were formerly regarded as relatively radioresistant tumors. In the past two decades, however, mounting evidence has shown an effect of radiotherapy (RT) on STS. Two randomized studies and several retrospective reports have indicated improved local control when surgical removal of high-grade STS was combined with RT 2, 8, 9, 10, 11, 12, 13, 14. The effect of RT has mainly been demonstrated after intralesional or marginal surgery, but improvements in local control after adding RT to wide margin surgery has also been reported 15, 16, 17. The effect of RT on low-grade malignant sarcomas is still controversial 9, 17, 18.
When the Scandinavian Sarcoma Group (SSG) was started in 1979, surgery with a wide margin was considered sufficient treatment of STS, and RT was used only for those with an intralesional or marginal margin. Because of the positive international experience of adjuvant RT, its use also increased in Scandinavia. In 1998, adjuvant RT was formally recommended by the SSG for intralesional and marginal margins, regardless of tumor depth, and for deep-seated, high-grade sarcoma, regardless of margin status (Clinical Protocol SSG XIII) (19). RT was recommended to begin as soon as the wound had healed. The only study on the importance of an early start of RT for STS found a better local recurrence-free survival rate (88%) in patients starting RT <4 months after surgery than in patients who started >4 months after surgery (62%) (20).
In 1986, the SSG established a register of soft tissue and bone sarcomas, including registration of detailed patient, tumor, treatment, and follow-up data. This register and the gradually increased use of RT gave us an opportunity to assess the effect of RT in relation to the surgical margins and histologic malignancy grade in STS patients treated at Scandinavian sarcoma centers between 1986 and 2005.
Section snippets
Patients and referral
The study was conducted in accordance with the Helsinki Declaration of 1975 (revised in 2000) and was approved by the Regional Committee for Medical Research Ethics and the Ombudsman for Privacy in Research, Norwegian Social Science Data Service.
The SSG Register currently contains information on >5,000 patients. It includes data on about 90% of all sarcomas treated in Sweden and Norway and is considered representative of the population. The remaining 10% of STSs not reported are mainly small
Results
The annual number of patients referred (before any surgery) increased with time. The fraction of wide surgical margin (including myectomy and compartmental margins) was similar, and the amputation rate did not change over time (Table 2).
Discussion
This study was of a large, prospective series of STSs treated at four sarcoma centers according to common guidelines and with complete follow-up. The LRRs decreased as the use of adjuvant RT increased. Our findings are in concordance with previous publications on the effect of RT for localized STS 2, 8, 9, 10, 11, 12, 13, 14. When we examined other treatment-related factors (surgical margin type, interval from surgery to the start of RT, use of adjuvant chemotherapy), we could not demonstrate
Conclusion
Adjuvant RT decreased the LRR of STSs, irrespective of surgical margin type, tumor depth, and malignancy grade. Tumor resection with an intralesional or a marginal margin necessitates RT. The effect of RT was small on low-grade tumors, irrespective of depth, after resection with a wide margin. The effect was moderate in high-grade, subcutaneous tumors resected with a wide margin. Whether this risk requires RT depends on the expected morbidity caused by surgical treatment of LR. RT had a
Acknowledgments
We are grateful to Tore Wenzel-Larsen, statistician, Center for Clinical Research, Haukeland University Hospital, Bergen, Norway; Anne-Lise Salbu, coordinator, Center for Bone and Soft Tissue Tumors, Haukeland University Hospital, Bergen, Norway; and Eva-Marie Olofsson, SSG-secretariat, Department of Cancer Epidemiology, Lund University Hospital, Lund, Sweden.
References (45)
- et al.
Prognostic factors in soft tissue sarcomas: the Aarhus experience
Eur J Cancer
(1998) - et al.
Limb-sparing therapy of extremity soft tissue sarcomas: Treatment outcome and long-term functional results
Eur J Cancer
(1994) - et al.
Local control of soft tissue sarcoma of the extremity: The experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy
Eur J Cancer
(1994) - et al.
Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity
Int J Radiat Oncol Biol Phys
(2000) - et al.
The effect of delayed postoperative irradiation on local control of soft tissue sarcomas of the extremity and torso
Int J Radiat Oncol Biol Phys
(2002) - et al.
Improved prognostication in soft tissue sarcoma: Independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays
Hum Pathol
(2005) - et al.
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial
Lancet
(2002) - et al.
Effect of delay in radiation in the combined modality treatment of breast cancer
Int J Radiat Oncol Biol Phys
(1993) Soft tissue sarcoma: Epidemiology and prognosis in 508 patients
Acta Orthop Scand Suppl
(1994)- et al.
High-grade extremity soft tissue sarcomas: Factors predictive of local recurrence and its effect on morbidity and mortality
Ann Surg
(2003)
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: An analysis of 225 patients
Cancer
A systematic overview of radiation therapy effects in soft tissue sarcomas
Acta Oncol
Local recurrence of soft tissue sarcoma: A Scandinavian Sarcoma Group project
Acta Orthop Scand Suppl
Evidence-based recommendations for local therapy for soft tissue sarcomas
J Clin Oncol
A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk
J Clin Oncol
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity
J Clin Oncol
The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy
Ann Surg
Local recurrence in adult soft-tissue sarcoma: A randomized trial of brachytherapy
Arch Surg
Local recurrence of deep-seated, high-grade, soft tissue sarcoma: 459 patients from the Scandinavian Sarcoma Group Register
Acta Orthop Scand
The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival
Cancer
Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma
J Clin Oncol
Radiation therapy for low-grade soft tissue sarcoma
Clin Orthop Relat Res
Cited by (121)
Real-world clinical outcomes with daily image-guided IMRT in extremity soft tissue sarcomas
2022, Cancer Treatment and Research CommunicationsRadiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline
2021, Practical Radiation OncologyCitation Excerpt :These unplanned procedures complicate options for subsequent appropriate oncologic management.8-10 The addition of radiation therapy (RT) to surgery allows excellent local control with surgical approaches that preserve organs and function.11-16 Questions arise regarding when RT should be used in addition to oncologic resection and how best to sequence surgery and RT when both are used.
Soft Tissue Sarcomas in Adolescents and Young Adults
2024, Journal of Clinical Oncology
Supported in part by the Swedish Children Cancer Society, Swedish Cancer Society, and Nordic Cancer Union.
N. L. Jebsen received funding from the National Competence Center for Sarcoma and from Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway.
Conflict of interest: none.